Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of pharmacological treatments on hemodynamics, cardiovascular reserve, exercise tolerance, and prognosis in HFpEF
jRCT1031220336Recruiting
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of empagliflozin, sacubitril + valsartan and spironolactone in heart failure with preserved ejection fraction (HFpEF). Primary endpoint: Change in estimated pulmonary artery systolic pressure during peak exercise. Started Sep 2022; status: recruiting.
02
Drugs
empagliflozinsacubitril + valsartanspironolactone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on jRCT1031220336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031220336.